. The practical issue that Pàez-Ribes et al. 1 and Ebos and colleagues 2 now raise through preclinical studies is whether anti-VEGF therapy could shorten patients' long-term survival. Pàez-Ribes et al. studied the effects of either anti-angio genic drugs or genetic ablation of the gene encoding a VEGF protein in mouse models of two cancers: glioblastoma, the deadliest of brain cancers, and pancreatic neuro endocrine tumours. They find that, although these treatments have antitumour effects, loss of VEGF signalling also increases tumour invasiveness and metastasis.
Ebos et al. 2 reached similar conclusions when they treated mice with VEGF-receptor inhibitors. Intriguingly, they found that whether these drugs prevented tumour growth or increased the likelihood of metastasis depended on tumour stage and the duration of treatment. Whereas sustained use of the drugs on established tumours significantly inhibited tumour growth, short-term treatment before the implantation of tumour cells into mice 'pre-conditioned' the animals for accelerated metastasis.
How do these findings relate to previous clinical observations? From experience in the clinic, single-agent anti-VEGF therapy is in effective for treating non-small-cell lung cancer, and metastatic breast and colorectal cancers. However, anti-VEGF agents -specifically, bevacizumab, a VEGF-neutralizing antibody -improve the effects of chemotherapy in patients with these tumour types 3 . It is likely that such effects of combined therapy are due to complex interactions between anti-VEGF and chemotherapeutic agents, and so are not directly comparable with the preclinical data 1, 2 . In addition, a study 8 that analysed data from a prospective database of more than 1,900 patients with metastatic colorectal cancer indicated that the overall survival of those given bevacizumab throughout their treatment, in combination with various chemotherapeutic agents, was much better than the results of any clinical trial in which anti-VEGF therapy was stopped after initial disease progressiontumour growth despite therapy. This observation, combined with the data alluded to above, suggests that the preclinical findings of Pàez-Ribes et al. and Ebos et al. should not dissuade oncologists from using anti-VEGF therapy in combination with chemotherapy. However, these studies 1,2 may be more relevant to patients with a form of liver cancer called hepatocellular carcinoma, and possibly those with kidney cancer 9, 10 . Single-agent anti-VEGF therapy in both of these patient groups improves survival with no clinically evident deleterious effects.
Investigators are currently awaiting the results of several clinical trials in patients at risk of harbouring undetectable metastatic tumours and who receive chemotherapy together with bevacizumab in the adjuvant setting, in an attempt to prevent these 'micrometastases' from growing. In particular, the outcome of a trial in which patients with colorectal carcinoma received six months of combination therapy followed by six months of bevacizumab alone is expected soon. Results gathered from such studies should be evaluated not only for cancer-progression-free and overall survival rates, but also for the pattern of tumour recurrence -that is, whether patients with cancer recurrence demonstrate widespread metastases, as seen in the preclinical studies 1, 2 . Observations in patients with recurrent glioblastoma who were treated with anti-VEGF therapy with or without the chemotherapeutic agent irinotecan seem to support some of the findings of Pàez-Ribes et al. and Ebos and colleagues. Unlike historical salvage therapies, which achieve low response rates of nominal duration, most patients with recurrent glioblastoma respond to anti-VEGF therapy, as is evidenced by both improved MRI (magnetic resonance imaging) scans and improvement in their neurological deficits. What's more, in many, these gratifying responses are meaningfully durable 11 . Nevertheless, most patients become resistant to anti-VEGF therapy, showing marked infiltration of tumour cells, and with some tumours spreading to other regions of the brain, such as the contralateral hemisphere, brainstem and leptomeninges (Fig. 1) ; progression is also often quick and rapidly fatal 11 . This observation supports the findings of Pàez-Ribes et al. 1 and Ebos et al.
2
, and together they indicate that, although anti-VEGF therapy may meaningfully improve the therapeutic outcome for some patients, resistance to this therapy can develop and may lead to more aggressive and widespread disease. These data therefore highlight the point that oncologists must carefully scrutinize clinical data, not only focusing on short-term endpoints, such as response rates and time to progression, but also patterns of failure, overall survival and quality of life.
On the basis of these findings 1,2,11 , should anti-VEGF therapy be limited in duration? As noted in the preclinical setting 1, 2 , even a short duration of anti-VEGF therapy can increase the likelihood of invasion and metastasis by tumour cells; yet in the clinic, acceleration of tumour growth and/or metastasis is rarely (if ever) noted after initiation of therapy. Some investigators have noted a 'tumour flare' on cessation of anti-VEGF therapy, but these observations are anecdotal. One approach to resolving this dilemma is to identify increases in the levels of soluble markers or mediators of tumour growth and/or metastasis just before starting anti-VEGF therapy. Indeed, an increase in levels of PlGF and HGF -potential 
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In a letter to the Times of March 15, Prof. Osler directs attention to the useful work which is being done by the Italian Society for the Study of Malaria, founded ten years ago, for the prevention of malarial diseases. The society has promoted legislation for the gratuitous distribution of quinine, has prepared quinine in its most agreeable forms, and has introduced into practice the mechanical measures based on the defence of the habitation and the individual from the bites of mosquitoes. The result is that the mortality from malaria in Italy has declined from 16,000 in 1902 to about 4000 in 1908 … the growth of our knowledge of the causation and prevention of malaria illustrates the stages through which so many of the great discoveries in medicine have had to pass, and is a striking example of the value of experimental methods in medical research. From Nature 18 March 1909.
